OTC Dermatologic Topical Corticosteroids Michael L. Koenig, Ph.D. Interdisciplinary Scientist Division of Over-the-Counter Drug Products Center for Drug.

Slides:



Advertisements
Similar presentations
Welcome to Medicines in My Home.
Advertisements

Over The Counter Drugs (OTC) Dina R. Utter MSN Student Viterbo University.
Regulatory History of Pediatric Cough/Cold Products Joint Meeting of the Nonprescription Drugs Advisory Committee (NDAC) and the Pediatric Advisory Committee.
Overview of Aspirin and NSAID’s Label Warnings William E. Gilbertson, PharmD. Division OTC Drug Products 1.
NDAC/PADAC Joint Meeting May 11, 2001 Cazemiro R. Martin Regulatory Review Chemist FDA, Division of OTC Drug Products.
Chapter 12 Skin Medications. Copyright © 2007 by Thomson Delmar Learning. ALL RIGHTS RESERVED.2 Skin Medications Skin is largest organ of the body Many.
Regulatory History and Attributes of Consumer Antiseptics Nonprescription Drugs Advisory Committee Meeting Silver Spring, Maryland October 20, 2005 Colleen.
Treatment for Poisonings
Treatment for Poisonings
1 Patterns of Use of OTC Topical Hydrocortisone Presented by Charles N. Ellis, MD Professor of Dermatology University of Michigan Medical School, and Chief.
Nonprescription Simvastatin in the United Kingdom Michael L. Koenig, Ph.D. Interdisciplinary Scientist Division of Over-the-Counter Drug Products Center.
The FDA’s Role in Medicine Safety and Use
Over-the-Counter Medicine Education
1 Petition to Convert Claritin®, Allegra® and Zyrtec® to OTC Status Robert Seidman, PharmD, MPH Chief Pharmacy Officer WellPoint Health Networks FDA Pulmonary.
Joint NDAC/PAC meeting October 18, 2007 OTC Cold and Cough Products: Use in Children Advisory Committee Meeting October 18, 2007 Joel Schiffenbauer, MD.
NDA/PADAC Joint Meeting Matthew R. Holman, Ph.D. Interdisciplinary Scientist FDA, CDER, Div. Of OTC Drug Products April 22,
Ipecac Syrup: Regulatory History Nonprescription Drugs Advisory Committee Meeting Arlene Solbeck, M.S. Interdisciplinary Scientist, Division of OTC Drug.
Atopic Dermatitis. Dermatitis Pattern of cutaneous inflammation – Acute: erythema, vesicles, pruritis – Chronic: dryness, scaling, lichenification, fissuring,
Overview of Acetaminophen Label Warnings William E. Gilbertson, PharmD. Division OTC Drug Products 1.
Drug Name: Verdeso (desonide)
1 Topical Antifungals for T. Pedis Labeling Issues Daiva Shetty, M.D. Division of Over-the-Counter Drug Products (HFD-560) Food and Drug Administration.
1. 2 Medicines are Drugs A medicine or drug… –changes how your body works, or –treats or prevents a disease or symptom.
Lesson 4 Treatment for Poisonings Many household products become poisons if they are used incorrectly. Knowing how to respond to accidental poisoning.
ACNE Common and chronic disorder of sebaceous glands Causes blackheads, cysts, pimples and scarring.
ATOPY. What is Atopic? Atopic syndrome is an allergic affecting parts of the body not in direct contact with the allergen. The origin of atopy.
Nonprescription Drugs Advisory Committee and the Dermatologic and Ophthalmic Drugs Advisory Committee March 24, 2005 Rx Topical Corticosteroids HPA Axis.
1 Regulatory History of OTC Phenylpropanolamine Hydrochloride (PPA) Robert L. Sherman Division of OTC Drug Products Center for Drug Evaluation and Research.
CHPA Comments on Efficacy and Labeling Issues for OTC Drug Products Used in the Treatment of Tinea Pedis CHPA Antifungal Task Group 6 May 2004.
1 Nonprescription Drugs and Dermatologic and Ophthalmic Drugs Joint Advisory Committee Meeting Over-the-Counter Antifungal Drug Products Treatment of Tinea.
NDAC December 14, Nonprescription Drugs Advisory Committee Meeting Silver Spring, Maryland December 14, 2007 Mary S. Robinson, MS Division of Nonprescription.
1. 2 Medicines are Drugs A medicine or drug… –changes how your body works, or –treats or prevents a disease or symptom.
Eczema By Ondine Legris.
FDA Case Studies Pediatric Oncology Subcommittee March 4, 2003.
Orlistat 60 mg Joint Meeting Nonprescription Drugs and Endocrinologic and Metabolic Drugs Advisory Committees January 23, 2006 Andrea Leonard-Segal, M.D.
Regulatory History of Aspirin Cardiovascular and Renal Drugs Advisory Committee Meeting Michelle M. Jackson, Ph.D. Division of Over-The-Counter Drug Products.
Cardiovascular Risk and NSAIDs Arthritis Advisory Committee Meeting November 29, 2006 Sharon Hertz, M.D. Deputy Director Division of Analgesia, Anesthesia,
Chapter 9 Preview Bellringer Key Ideas What Are Drugs?
Eczema Lauren Childs 2 nd Hour. What Is Eczema? Eczema is an allergic condition that affects the skin. It occurs in atopic people that are extra sensitive.
History and Overview of OTC Topical Antifungal Drug Products Houda Mahayni, R. Ph., Ph.D. Division of Over-the-Counter Drug Products.
1 Assessing Cancer Risk & Assuring Safe Use of Topical Immunosuppressants: Recent History Susan K. Cummins, MD, MPH Medical Team Leader OCTAP and OPT.
Perspectives on Enhancing Consumer Outcomes with Topical Antifungals
Over the Counter & Rx Drugs
Joint NDAC/DODAC Advisory Committee Meeting March 24, 2005 Rx Topical Corticosteroids and Testing for Adrenal Suppression Markham C. Luke, M.D., Ph.D.
AFAMS Dermatologicals EO Part 20. AFAMS Overview of Lesson (Insert Dari) Antifungals for dermatologic use Emollients and protectives Antipuretics.
Over-the-Counter Drug Products Over-the-Counter (OTC) drug products are those drugs that are available to consumers without a prescription. There.
Prilosec1 ® 20 mg Tablets Rx to OTC Switch Daiva Shetty, M.D. Division of Over-the-Counter Drug Products (HFD-560) Food and Drug Administration 1.
Copyright © by Holt, Rinehart and Winston. All rights reserved. ResourcesChapter menu Understanding Drugs and Medicines Chapter 9.
Monograph Regulation of Weight Control Products for Over-The-Counter (OTC) Use Joint Nonprescription Drugs Advisory Committee and Endocrine and Metabolic.
Background Derma-Smoothe/FS ® (Fluocinolone acetonide ) Contains 0.01% fluocinolone acetonide in an oil base solution, Categorized as a low to medium potency.
Section 2: Drugs as Medicines
Medicines Drugs Unit Lecture 2. Types of Medicines A prescription is a written order from a doctor for a specific medicine. Over-the-counter (OTC) medicines.
Nonprescription Drugs Advisory Committee Meeting Charles J. Ganley, M.D. Division of OTC Drug Products September 19, 2002.
Nonprescription Drugs Advisory Committee Meeting Charles J. Ganley, M.D. Division of OTC Drug Products September 20, 2002.
Topical Corticosteroid Adverse Events in Pediatric Patients Analysis of Postmarketing Reports Pediatric Advisory Subcommittee of the Anti-Infective Drugs.
Food and Drug Administration Division of Pulmonary and Allergy Drug Products Summary Comments - Orally Inhaled and Intranasal Budesonide and Fluticasone.
Prednisone Uses Stress Prednisone Cost foods to avoid on prednisone dealing with prednisone mood swings oral prednisone dosage for poison oak can prednisone.
OVER THE COUNTER MEDS INTRODUCTION No prescriptions are necessary and no questions need to be answered to attain these drugs OTC med use saves.
1. 2 Medicines are Drugs A medicine or drug… –changes how your body works, or –treats or prevents a disease or symptom.
Integumentary System Diseases and Abnormal Conditions
Atopic Eczema in children
Eucrisa™ - Crisaborole
Appropriate use and potential side effects of TCS
Paediatric Atopic Eczema
ANALYSIS OF PATIENT-REPORTED SYMPTOMS WITH RESPECT TO TCS USAGE:
Medicines and Drugs Chapter 23 Mr. Martin.
Too Early for an Itchy Rash Small Group Teaching Problem Based Learning Department of Dermatology College of Medicine King Saud University Riyadh.
Rash on the Manhood: 5 Common Causes and How to Treat Them
Treatment for Poisonings Pg
Treatment for Poisonings
Lesson 2: Diseases and Disorders
Presentation transcript:

OTC Dermatologic Topical Corticosteroids Michael L. Koenig, Ph.D. Interdisciplinary Scientist Division of Over-the-Counter Drug Products Center for Drug Evaluation and Research

2 Joint DODAC/NDAC Meeting March 24, 2005 Overview 1.Regulation of OTC Drugs 2.Regulatory History of Hydrocortisone 3.Current Labeling of Hydrocortisone

3 Joint DODAC/NDAC Meeting March 24, 2005 Regulation of OTC Drugs NDA (New Drug Application) –Drug product-specific –Confidential Monograph –Active ingredient-specific –Public

4 Joint DODAC/NDAC Meeting March 24, 2005 OTC Monographs OTC Drug Review initiated in 1972 > 200,000 OTC drug products 700 active ingredients in 26 therapeutic categories

5 Joint DODAC/NDAC Meeting March 24, 2005 OTC Monographs Category I: GRASE (Generally Recognized as Safe and Effective) Category II: not GRASE Category III: cannot determine if safe and effective Advisory Review Panel

6 Joint DODAC/NDAC Meeting March 24, 2005 OTC Monographs Category I: GRASE Category II: not GRASE Category III: cannot determine if safe and effective ANPR

7 Joint DODAC/NDAC Meeting March 24, 2005 OTC Monographs ANPR TFM Comments

8 Joint DODAC/NDAC Meeting March 24, 2005 OTC Monographs TFM Comments Data FM

9 Joint DODAC/NDAC Meeting March 24, 2005 Regulatory History of Hydrocortisone

10 Joint DODAC/NDAC Meeting March 24, 2005 Regulatory History of Hydrocortisone Introduced as Rx drug (1952) Rx-to-OTC switch rejected (1957) –Failure to show safety for self-medication –More testing on absorption through the skin Included with other active ingredients in review of external analgesics ( )

11 Joint DODAC/NDAC Meeting March 24, 2005 Regulatory History of Hydrocortisone ANPR (1979) Lack of adverse local effects –Striae –Telangiectasia –Pustular eruptions and crusting

12 Joint DODAC/NDAC Meeting March 24, 2005 Regulatory History of Hydrocortisone ANPR (1979) Lack of systemic effects –Percutaneous absorption –Eosinophil count –Urinary levels of 17-hydroxysteroids and 17- ketosteroids –Blood glucose levels –Serum sodium –Plasma cortisol ↑ in response to insulin

13 Joint DODAC/NDAC Meeting March 24, 2005 Regulatory History of Hydrocortisone No HPA Axis Suppression Munro and Clift, Br. J. Dermatol., 1973 (TAB 5) –40 patients with eczema, psoriasis –Long term treatment (95% > 10 months) –Corticosteroid combinations 10 included 1% hydrocortisone acetate –10/10: normal insulin stress response

14 Joint DODAC/NDAC Meeting March 24, 2005 Regulatory History of Hydrocortisone Serious Adverse Events ( ) 1960: Temporary growth retardation in 5.5 year old –1% hydrocortisone for 16 months 1962: Temporary growth retardation in infant –1% hydrocortisone twice daily for 6 months (total body) 1966: Rapid gain in body weight in 3-week old –0.25% hydrocortisone three times daily for 8.5 days –2100 mg/m 2 body surface area

15 Joint DODAC/NDAC Meeting March 24, 2005 Regulatory History of Hydrocortisone Panel Recommendations 0.25 – 0.5% hydrocortisone GRASE Recommended labeling: –Indication – temporary relief of minor skin irritations, itching, and rashes due to eczema, dermatitis… –Warnings Stop use if condition worsens or lasts > 7 days Do not use on children under 2 years of age –Directions – Apply to affected area not more than 3 to 4 times daily

16 Joint DODAC/NDAC Meeting March 24, 2005 Regulatory History of Hydrocortisone TFM (1983) FDA position –Agreed 0.25 – 0.5% hydrocortisone GRASE –Some labeling modifications Temporary relief of itching associated with minor skin irritations and rashes due to… Stop use if condition worsens or lasts > 7 days or if symptoms clear up and occur again within a few days

17 Joint DODAC/NDAC Meeting March 24, 2005 Regulatory History of Hydrocortisone Amended TFM (1990) Citizen Petition requested increase in dosage strength to 1% Data and literature review 0.25 – 1.0% hydrocortisone GRASE Additional labeling modifications –Do not use any other hydrocortisone product for the treatment of diaper rash

18 Joint DODAC/NDAC Meeting March 24, 2005 Regulatory History of Hydrocortisone FM (20??) Pending Manufacturers generally comply with TFM and amended TFM Continuing review of data

19 Joint DODAC/NDAC Meeting March 24, 2005 Hydrocortisone Does Not Suppress HPA Axis Published StudynHydrocortisone (%) Duration of Treatment Munro, *14 days Marten et al., days Patel et al., years Lucky et al., days Ellison et al., – 17.7 years * Hydrocortisone acetate

20 Joint DODAC/NDAC Meeting March 24, 2005 Current Labeling of Hydrocortisone

21 Joint DODAC/NDAC Meeting March 24, 2005 Monograph Labeling: Hydrocortisone Drug Facts Active ingredient Purpose Hydrocortisone (1%)…………………………………………....Anti-itch Uses ■ temporarily relieves itching associated with minor skin irritations, inflammation, and rashes due to: ■ eczema ■ poison ivy, oak, sumac ■ insect bites ■ soaps ■ detergents ■ cosmetics ■ jewelry ■ seborrheic dermatitis ■ psoriasis ■ and for external genital or anal itching ■ other uses of this product should be only under the advice and supervision of a doctor Warnings External use only Do not use ■ for the treatment of diaper rash. Consult a doctor. ■ in the genital area if you have a vaginal discharge. Consult a doctor. Drug Facts (continued) When using this product ■ avoid contact with the eyes ■ do not exceed the recommended daily dosage unless directed by a doctor ■ do not cover treated skin ■ do not use any other hydrocortisone product ■ do not put directly in rectum using fingers or any mechanical device Stop use and ask a doctor if ■ condition worsens ■ symptoms persist for more than 7 days or clear up and occur again within a few days ■ rectal bleeding occurs Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away. Directions ■ adults and children 2 years of age and older: apply to affected area not more than 3 to 4 times daily. ■ children under 2 years of age: Do not use. Consult a doctor.

22 Joint DODAC/NDAC Meeting March 24, 2005 Monograph Labeling: Hydrocortisone Drug Facts Active ingredient Purpose Hydrocortisone (1%)…………………………………………....Anti-itch Uses ■ temporarily relieves itching associated with minor skin irritations, inflammation, and rashes due to: ■ eczema ■ poison ivy, oak, sumac ■ insect bites ■ soaps ■ detergents ■ cosmetics ■ jewelry ■ seborrheic dermatitis ■ psoriasis ■ and for external genital or anal itching ■ other uses of this product should be only under the advice and supervision of a doctor Warnings External use only Do not use ■ for the treatment of diaper rash. Consult a doctor. ■ in the genital area if you have a vaginal discharge. Consult a doctor. Drug Facts (continued) When using this product ■ avoid contact with the eyes ■ do not exceed the recommended daily dosage unless directed by a doctor ■ do not cover treated skin ■ do not use any other hydrocortisone product ■ do not put directly in rectum using fingers or any mechanical device Stop use and ask a doctor if ■ condition worsens ■ symptoms persist for more than 7 days or clear up and occur again within a few days ■ rectal bleeding occurs Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away. Directions ■ adults and children 2 years of age and older: apply to affected area not more than 3 to 4 times daily. ■ children under 2 years of age: Do not use. Consult a doctor. temporarily relieves itching associated with minor skin irritations, inflammation and rashes due to: ■ eczema■ poison ivy, oak, sumac ■ insect bites■ soaps ■ detergents■ cosmetics ■ jewelry■ seborrheic dermatitis ■ psoriasis■ and for external genital or anal itching Stop use and ask a doctor if ■ symptoms persist for more than 7 days or clear up and occur again within a few days ■ apply to affected area not more than 3 to 4 times daily. ■ children under 2 years of age: Do not use. Consult a doctor.

23 Joint DODAC/NDAC Meeting March 24, 2005 temporarily relieves itching of minor skin irritations, inflammation and rashes… symptoms persist for more than 7 days or clear up and occur again within a few days ■ apply to affected area not more than 3 to 4 times daily ■ children under 2 years of age: do not use, ask a doctor